@entity470 , @entity876 mutation, and pathological response predict survival in XXXX with locally advanced @entity418 treated with preoperative chemoradiotherapy.

@entity1 @entity589 @entity588 @entity5 @entity470 @entity957 @entity900 @entity876 @entity418 @entity1349 @entity420 @entity1487
PURPOSE: Despite the availability of cellular markers associated with cell cycle, apoptosis, and DNA repair, predictive factors for pathological complete response (CR) and @entity1349 ( @entity1349 ) are few in @entity1 with locally advanced @entity418 . This study evaluates the role of clinical and cellular markers in predicting CR and @entity1349 in @entity1 with @entity418 . EXPERIMENTAL DESIGN: @entity1 were treated with infusional @entity900 and @entity1487 combined with daily radiotherapy followed by esophagectomy. @entity5 (n = 54) were analyzed for @entity470 ( @entity470 ), @entity589 , and @entity588 expression by immunohistochemistry and for @entity876 mutations by direct DNA sequencing of exons 5-8. Clinical covariates included @entity1 ' age at enrollment; gender; Barrett's metaplasia; and @entity5 location, histology, and differentiation. Logistic regression and survival analyses were used to evaluate the predictors. RESULTS: Age ranged from 32 to 75 years; most @entity1 were male (45 male; 9 female); and @entity5 were distal (47 distal; 7 mid), @entity420 (41 @entity420 ; 13 @entity957 ), and moderately differentiated (33 moderate; 6 well; 15 poor). Female gender predicted CR (odds ratio 7.5; 95% confidence interval, 1.4-41). The @entity1349 was 43% at 5 years. Presence of CR (P < 0.001 log rank) and @entity876 mutation (P = 0.051 log rank) correlated with increased @entity1349 , whereas increased @entity470 expression predicted poor @entity1349 (P = 0.009 log rank). @entity470 remained significant when adjusted for clinical covariates. There was a trend toward increased @entity1349 related to @entity5 differentiation and decreased @entity588 . CONCLUSIONS: These data suggest that @entity470 and @entity876 mutation may be used as both outcome predictors and targets for molecular therapy for @entity418 .
